Company: Anokion Inc.
Job title: Chief Scientific Officer
Informing Late-Stage Biomarker Strategies: Learnings from Early In-Human Studies to Inform Future Trial Design 1:15 pm
Going from cell-based assays into symptoms or disease markers for tolerance studies Delving into preclinical and clinical development for antigen specific autoimmune diseaseRead more
day: Conference Day One
Panel & Audience Discussion: Supercharging Antigen-Specific Approaches to Autoimmune Disease Patients: Evaluating the Next Steps to Move Forward as a Field 3:00 pm
Selecting antigens – what makes a ‘good’ antigen? Assessing preclinical models – what should we move towards for regulatory buy-in? Creating a biomarker toolbox – what biomarkers could be a tolerance endpoint? Honing clinical study design – what are key considerations for tolerance?Read more
day: Conference Day Two